Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension

NCT00325442 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT00325442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00325442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
December 31, 2010
Enrollment
354 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension